Inhibikase Therapeutics, Inc. (IKT)

Inhibikase Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	0.26	0.12	3.1	0.7
Revenue Growth (YoY)	-	-	111.03%	-96.02%	343.92%	-37.79%
Cost of Revenue	17.21	17.21	13.62	12.03	11.36	0.89
Gross Profit	-17.21	-17.21	-13.36	-11.91	-8.26	-0.2
Selling, General & Admin	22.52	11.38	6.73	6.22	6.51	2.62
Operating Expenses	33.92	11.38	6.73	6.22	6.51	2.62
Operating Income	-51.13	-28.59	-20.09	-18.13	-14.77	-2.82
Interest Expense	-	-	-	-	-0.02	-0.03
Interest & Investment Income	3.47	1.07	1.06	0.07	-	-
Pretax Income	-47.66	-27.52	-19.03	-18.05	-14.79	-2.85
Net Income	-47.66	-27.52	-19.03	-18.05	-14.79	-2.85
Net Income to Common	-47.66	-27.52	-19.03	-18.05	-14.79	-2.85
Shares Outstanding (Basic)	85	24	6	4	3	1
Shares Outstanding (Diluted)	85	24	6	4	3	1
Shares Change (YoY)	1080.00%	293.35%	42.74%	39.15%	121.72%	0.39%
EPS (Basic)	-0.56	-1.16	-3.16	-4.28	-4.87	-2.08
EPS (Diluted)	-0.56	-1.16	-3.16	-4.28	-4.87	-2.08
Free Cash Flow	-25.63	-19.15	-18.1	-17.59	-14.3	-1.13
Free Cash Flow Per Share	-0.30	-0.81	-3.00	-4.17	-4.71	-0.82
Gross Margin	-	-	-	-	-266.35%	-27.97%
Operating Margin	-	-	-7711.98%	-14686.17%	-476.23%	-403.52%
Profit Margin	-	-	-7304.73%	-14625.86%	-476.88%	-407.73%
Free Cash Flow Margin	-	-	-6947.87%	-14253.37%	-461.10%	-161.69%
EBITDA	-51.06	-28.56	-19.91	-18.12	-	-
D&A For EBITDA	0.07	0.03	0.18	0.01	-	-
EBIT	-51.13	-28.59	-20.09	-18.13	-14.77	-2.82
Revenue as Reported	-	-	0.26	0.12	3.1	0.7

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q